Roche, Giredestrant, Everolimus, evERA, Breast Cancer, ER-Positive Breast Cancer, HER2-Negative, ESR1 Mutation, SERD, Selective Estrogen Receptor Degrader

BASEL, Switzerland — October 1, 2026 Roche announced detailed results from the Phase III evERA Breast Cancer study evaluating...